FSTX - F-star Therapeutics tumbles on report buyer doesn't expect CFIUS approval
- F-star Therapeutics plunged 20% on a report that the buyer of the company doesn't expect a favorable outcome from the Committee on Foreign Investment or CFIUS review of the deal.
- invoX Pharma, the unit of China’s Sino Biopharmaceutical that's is buying F-star ( NASDAQ: FSTX ), doesn't believe there is a path forward with the Jan. 31 merger end date approaching, according to a Dealreporter item, which cited a source familiar.
- Late last month a regulatory filing indicated that CFIUS issued an interim order blocking its planned sale to Sino Biopharmaceutical.
- Developing story ...
For further details see:
F-star Therapeutics tumbles on report buyer doesn't expect CFIUS approval